+Follow
Nevv
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Nevv
11-14
Nvidia
Big Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?
Nevv
2024-06-14
Share your opinion about this news…
US Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4106902938818860","uuid":"4106902938818860","gmtCreate":1643805156794,"gmtModify":1715152267545,"name":"Nevv","pinyin":"nevv","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":628969893928976,"gmtCreate":1794600768695,"gmtModify":1794618400164,"author":{"id":"4106902938818860","authorId":"4106902938818860","name":"Nevv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106902938818860","idStr":"4106902938818860"},"themes":[],"title":"","htmlText":"Nvidia","listText":"Nvidia","text":"Nvidia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/628969893928976","repostId":"1193619814","repostType":2,"repost":{"id":"1193619814","kind":"video","weMediaInfo":{"introduction":"Videos: US & Hong Kong IPO Coverage","home_visible":1,"media_name":"Hong Kong & US IPO Tracker","id":"1085354563","head_image":"https://community-static.tradeup.com/news/9d168587694f27b8ce20b3b76cc3250e"},"pubTimestamp":1794532015,"share":"https://ttm.financial/m/news/1193619814?lang=en_US&edition=fundamental","pubTime":"2026-11-13 09:06","market":"hk","language":"en","title":"Big Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?","url":"https://stock-news.laohu8.com/highlight/detail?id=1193619814","media":"Hong Kong & US IPO Tracker","summary":"","content":"","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1085354563\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/9d168587694f27b8ce20b3b76cc3250e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Hong Kong & US IPO Tracker </p>\n<p class=\"h-time\">2026-11-13 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5447.webp","relate_stocks":{"NVDS":"1.5倍做空NVDA ETF-Tradr","AMDY":"AMD期权收益策略ETF-YieldMax","MRVL":"迈威尔科技","GOOGL":"谷歌A","MVLL":"2倍做多MRVL ETF-GraniteShares","NVDU":"2倍做多NVDA ETF-Direxion","GS":"高盛","AVGC":"2倍做多AVGO ETF-Corgi","AVL":"2倍做多AVGO ETF-Direxion","MS":"摩根士丹利","NVDW":"NVDA周配息ETF-Roundhill","GOOG":"谷歌","GOOL":"Leverage Shares 2X Long GOOGL Daily ETF","AMD":"美国超微公司","ANT":"Anthropic","DAMD":"2倍做空AMD ETF-Defiance","DIPS":"做空NVDA期权收益策略ETF-YieldMax","GOOP":"KURV YIELD PREMIUM STRATEGY GOOGLE (GOOGL) ETF","AMDC":"Corgi AMD 2x Daily ETF","NVDX":"2倍做多NVDA ETF-T-Rex","AVGG":"2倍做多AVGO ETF-Leverage Shares","NVC":"Corgi NVDA 2x Daily ETF","GOOW":"Roundhill GOOGL WeeklyPay ETF","ANV":"GraniteShares Autocallable NVDA ETF","AMDD":"1倍做空AMD ETF-Direxion","NVDY":"NVDA期权收益策略ETF-YieldMax","AVS":"1倍做空AVGO ETF-Direxion","TSMZ":"1倍做空TSM ETF-Direxion","STSM":"Defiance Daily Target 2X Short TSM ETF","NVD":"2倍做空NVDA ETF-GraniteShares","AMDG":"2倍做多AMD ETF- Leverage Shares","GOOX":"2倍做多GOOG ETF-T-REX","GGLL":"2倍做多GOOGL-Direxion","TSMG":"2倍做多TSM ETF- Leverage Shares","AVGU":"2倍做多AVGO ETF-GraniteShares","NVYY":"GraniteShares YieldBOOST NVDA ETF","NVDB":"ProShares Ultra NVDA ETF","07388":"南方两倍做空英伟达","MRVU":"Direxion Daily MRVL Bull 2X ETF","GGLS":"1倍做空GOOGL ETF-Direxion","NVII":"Rex NVDA Growth & Income ETF","AMDL":"2倍做多AMD ETF-GraniteShares","GOOY":"GOOGL期权收益策略ETF-YieldMax","NVDD":"1倍做空NVDA ETF-Direxion","TSMU":"2倍做多TSM ETF-GraniteShares","MRVX":"CORGI MRVL 2X DAILY ETF","AVGW":"Roundhill AVGO WeeklyPay ETF","NVDG":"2倍做多NVDA ETF- Leverage Shares","AVGO":"博通","TWSC":"Corgi TSM 2x Daily ETF","GOGL":"2倍做多GOOGL ETF-Corgi","TSMX":"2倍做多TSM ETF-Direxion","NVDA":"英伟达","AMUU":"2倍做多AMD ETF-Direxion","GOU":"GraniteShares 2x Long GOOGL Daily ETF","AVGX":"2倍做多AVGO ETF-Defiance","TSM":"台积电","NVDL":"2倍做多NVDA ETF-GraniteShares","TSMY":"TSM期权收益策略ETF-YieldMax","07788":"南方两倍做多英伟达","NVDQ":"2倍做空NVDA ETF-T-Rex","AMYY":"GraniteShares YieldBOOST AMD ETF","AMDW":"Roundhill AMD WeeklyPay ETF","NVDO":"2倍上限加速NVDA ETF-Leverage Shares"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193619814","news_type":1,"symbols_score_info":{"STSM":0.6,"NVDW":0.6,"AVL":0.6,"07388":0.6,"AMDW":0.6,"TSMX":0.6,"GOOX":0.6,"GOOW":0.6,"MRVL":2,"AVGU":0.6,"MRVU":0.6,"ANV":0.6,"AVS":0.6,"GOOGL":2,"NVDG":0.6,"AMD":2,"AMDG":0.6,"ANT":2,"AVGO":2,"AVGX":0.6,"TSM":2,"TSMZ":0.6,"TWSC":0.6,"GS":2,"GGLS":0.6,"MS":2,"NVC":0.6,"NVD":0.6,"NVDA":2,"NVDQ":0.6,"GGLL":0.6,"GOGL":0.6,"GOOG":2,"MVLL":0.6,"NVDB":0.6,"NVYY":0.6,"AVGG":0.6,"TSMU":0.6,"AMYY":0.6,"DAMD":0.6,"07788":0.6,"AMUU":0.6,"AMDY":0.6,"GOOL":0.6,"GOOP":0.6,"GOU":0.6,"NVDO":0.6,"NVDS":0.6,"MRVX":0.6,"TSMY":0.6,"NVII":0.6,"DIPS":0.6,"NVDU":0.6,"AMDD":0.6,"NVDD":0.6,"AVGC":0.6,"AMDL":0.6,"AVGW":0.6,"AMDC":0.6,"NVDL":0.6,"NVDY":0.6,"TSMG":0.6,"NVDX":0.6,"GOOY":0.6}},"isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":316597740753192,"gmtCreate":1718322106257,"gmtModify":1718329975324,"author":{"id":"4106902938818860","authorId":"4106902938818860","name":"Nevv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106902938818860","idStr":"4106902938818860"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/316597740753192","repostId":"2443652690","repostType":4,"repost":{"id":"2443652690","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1718320200,"share":"https://ttm.financial/m/news/2443652690?lang=en_US&edition=fundamental","pubTime":"2024-06-14 07:10","market":"us","language":"en","title":"US Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2443652690","media":"Reuters","summary":"June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or","content":"<html><head></head><body><p>June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.</p><p>The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.</p><p>BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.</p><p>The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0ed6740facea1f17e72184b80e974bb8\" tg-width=\"870\" tg-height=\"626\"/></p><p>It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.</p><p>Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.</p><p>"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body," the HHS said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-06-14 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.</p><p>The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.</p><p>BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.</p><p>The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0ed6740facea1f17e72184b80e974bb8\" tg-width=\"870\" tg-height=\"626\"/></p><p>It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.</p><p>Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.</p><p>"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body," the HHS said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc.","BK4551":"寇图资本持仓","BK4139":"生物科技","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4009":"广告","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2443652690","content_text":"June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.\"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body,\" the HHS said.","news_type":1,"symbols_score_info":{"VXRT":0.9}},"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":628969893928976,"gmtCreate":1794600768695,"gmtModify":1794618400164,"author":{"id":"4106902938818860","authorId":"4106902938818860","name":"Nevv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106902938818860","idStr":"4106902938818860"},"themes":[],"title":"","htmlText":"Nvidia","listText":"Nvidia","text":"Nvidia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/628969893928976","repostId":"1193619814","repostType":2,"repost":{"id":"1193619814","kind":"video","weMediaInfo":{"introduction":"Videos: US & Hong Kong IPO Coverage","home_visible":1,"media_name":"Hong Kong & US IPO Tracker","id":"1085354563","head_image":"https://community-static.tradeup.com/news/9d168587694f27b8ce20b3b76cc3250e"},"pubTimestamp":1794532015,"share":"https://ttm.financial/m/news/1193619814?lang=en_US&edition=fundamental","pubTime":"2026-11-13 09:06","market":"hk","language":"en","title":"Big Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?","url":"https://stock-news.laohu8.com/highlight/detail?id=1193619814","media":"Hong Kong & US IPO Tracker","summary":"","content":"","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Investors Pile In: What’s Driving Demand for Anthropic’s Mega IPO?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1085354563\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/9d168587694f27b8ce20b3b76cc3250e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Hong Kong & US IPO Tracker </p>\n<p class=\"h-time\">2026-11-13 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5447.webp","relate_stocks":{"NVDS":"1.5倍做空NVDA ETF-Tradr","AMDY":"AMD期权收益策略ETF-YieldMax","MRVL":"迈威尔科技","GOOGL":"谷歌A","MVLL":"2倍做多MRVL ETF-GraniteShares","NVDU":"2倍做多NVDA ETF-Direxion","GS":"高盛","AVGC":"2倍做多AVGO ETF-Corgi","AVL":"2倍做多AVGO ETF-Direxion","MS":"摩根士丹利","NVDW":"NVDA周配息ETF-Roundhill","GOOG":"谷歌","GOOL":"Leverage Shares 2X Long GOOGL Daily ETF","AMD":"美国超微公司","ANT":"Anthropic","DAMD":"2倍做空AMD ETF-Defiance","DIPS":"做空NVDA期权收益策略ETF-YieldMax","GOOP":"KURV YIELD PREMIUM STRATEGY GOOGLE (GOOGL) ETF","AMDC":"Corgi AMD 2x Daily ETF","NVDX":"2倍做多NVDA ETF-T-Rex","AVGG":"2倍做多AVGO ETF-Leverage Shares","NVC":"Corgi NVDA 2x Daily ETF","GOOW":"Roundhill GOOGL WeeklyPay ETF","ANV":"GraniteShares Autocallable NVDA ETF","AMDD":"1倍做空AMD ETF-Direxion","NVDY":"NVDA期权收益策略ETF-YieldMax","AVS":"1倍做空AVGO ETF-Direxion","TSMZ":"1倍做空TSM ETF-Direxion","STSM":"Defiance Daily Target 2X Short TSM ETF","NVD":"2倍做空NVDA ETF-GraniteShares","AMDG":"2倍做多AMD ETF- Leverage Shares","GOOX":"2倍做多GOOG ETF-T-REX","GGLL":"2倍做多GOOGL-Direxion","TSMG":"2倍做多TSM ETF- Leverage Shares","AVGU":"2倍做多AVGO ETF-GraniteShares","NVYY":"GraniteShares YieldBOOST NVDA ETF","NVDB":"ProShares Ultra NVDA ETF","07388":"南方两倍做空英伟达","MRVU":"Direxion Daily MRVL Bull 2X ETF","GGLS":"1倍做空GOOGL ETF-Direxion","NVII":"Rex NVDA Growth & Income ETF","AMDL":"2倍做多AMD ETF-GraniteShares","GOOY":"GOOGL期权收益策略ETF-YieldMax","NVDD":"1倍做空NVDA ETF-Direxion","TSMU":"2倍做多TSM ETF-GraniteShares","MRVX":"CORGI MRVL 2X DAILY ETF","AVGW":"Roundhill AVGO WeeklyPay ETF","NVDG":"2倍做多NVDA ETF- Leverage Shares","AVGO":"博通","TWSC":"Corgi TSM 2x Daily ETF","GOGL":"2倍做多GOOGL ETF-Corgi","TSMX":"2倍做多TSM ETF-Direxion","NVDA":"英伟达","AMUU":"2倍做多AMD ETF-Direxion","GOU":"GraniteShares 2x Long GOOGL Daily ETF","AVGX":"2倍做多AVGO ETF-Defiance","TSM":"台积电","NVDL":"2倍做多NVDA ETF-GraniteShares","TSMY":"TSM期权收益策略ETF-YieldMax","07788":"南方两倍做多英伟达","NVDQ":"2倍做空NVDA ETF-T-Rex","AMYY":"GraniteShares YieldBOOST AMD ETF","AMDW":"Roundhill AMD WeeklyPay ETF","NVDO":"2倍上限加速NVDA ETF-Leverage Shares"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193619814","news_type":1,"symbols_score_info":{"STSM":0.6,"NVDW":0.6,"AVL":0.6,"07388":0.6,"AMDW":0.6,"TSMX":0.6,"GOOX":0.6,"GOOW":0.6,"MRVL":2,"AVGU":0.6,"MRVU":0.6,"ANV":0.6,"AVS":0.6,"GOOGL":2,"NVDG":0.6,"AMD":2,"AMDG":0.6,"ANT":2,"AVGO":2,"AVGX":0.6,"TSM":2,"TSMZ":0.6,"TWSC":0.6,"GS":2,"GGLS":0.6,"MS":2,"NVC":0.6,"NVD":0.6,"NVDA":2,"NVDQ":0.6,"GGLL":0.6,"GOGL":0.6,"GOOG":2,"MVLL":0.6,"NVDB":0.6,"NVYY":0.6,"AVGG":0.6,"TSMU":0.6,"AMYY":0.6,"DAMD":0.6,"07788":0.6,"AMUU":0.6,"AMDY":0.6,"GOOL":0.6,"GOOP":0.6,"GOU":0.6,"NVDO":0.6,"NVDS":0.6,"MRVX":0.6,"TSMY":0.6,"NVII":0.6,"DIPS":0.6,"NVDU":0.6,"AMDD":0.6,"NVDD":0.6,"AVGC":0.6,"AMDL":0.6,"AVGW":0.6,"AMDC":0.6,"NVDL":0.6,"NVDY":0.6,"TSMG":0.6,"NVDX":0.6,"GOOY":0.6}},"isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":316597740753192,"gmtCreate":1718322106257,"gmtModify":1718329975324,"author":{"id":"4106902938818860","authorId":"4106902938818860","name":"Nevv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106902938818860","idStr":"4106902938818860"},"themes":[],"title":"","htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/316597740753192","repostId":"2443652690","repostType":4,"repost":{"id":"2443652690","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1718320200,"share":"https://ttm.financial/m/news/2443652690?lang=en_US&edition=fundamental","pubTime":"2024-06-14 07:10","market":"us","language":"en","title":"US Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2443652690","media":"Reuters","summary":"June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or","content":"<html><head></head><body><p>June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.</p><p>The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.</p><p>BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.</p><p>The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0ed6740facea1f17e72184b80e974bb8\" tg-width=\"870\" tg-height=\"626\"/></p><p>It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.</p><p>Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.</p><p>"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body," the HHS said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Government to Fund up to $500 Mln for Studies on Oral, Nasal COVID Vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-06-14 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.</p><p>The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.</p><p>BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.</p><p>The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0ed6740facea1f17e72184b80e974bb8\" tg-width=\"870\" tg-height=\"626\"/></p><p>It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.</p><p>Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.</p><p>"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body," the HHS said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc.","BK4551":"寇图资本持仓","BK4139":"生物科技","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4009":"广告","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2443652690","content_text":"June 13 (Reuters) - The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.BARDA, which helps companies develop medical supplies to address public health threats, is a part of HHS.The project is awarding up to $453 million to Vaxart for a study that will evaluate its oral COVID vaccine. The company's shares more than doubled to $1.79 after market.It is also awarding privately held Castlevax and Cyanvac around $34 million and $40 million, respectively, to develop their intranasal vaccine candidates.Each trial will enroll 10,000 volunteers and compare the efficacy and safety of the investigational vaccines to FDA-licensed vaccines.\"Currently approved COVID-19 vaccines are administered intramuscularly and, while extremely effective, are limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose and gut, where the SARS-CoV-2 virus first enters the body,\" the HHS said.","news_type":1,"symbols_score_info":{"VXRT":0.9}},"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}